| Mr Raycho Genchev Kurkchijski, MD | |
|
302 University Blvd, Round Rock, TX 78665-1032 | |
| (512) 509-0200 | |
| Not Available |
| Full Name | Mr Raycho Genchev Kurkchijski |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 302 University Blvd, Round Rock, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750309415 | NPI | - | NPPES |
| 630107045 | Medicaid | AL | |
| 51000149 | Other | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 00026167 (Alabama) | Secondary |
| 207Q00000X | Family Medicine | N5794 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center - Round Rock | Round rock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scott And White Clinic | 8123923604 | 2131 |
News Archive
Takeda Pharmaceutical Company Limited, today announced a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE in patients with hemophilia A, presented as an oral presentation at the World Federation of Hemophilia Virtual Summit 2020.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
› Verified 8 days ago
| Entity Name | Scott & White Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093779704 PECOS PAC ID: 8123923604 Enrollment ID: O20031223000640 |
News Archive
Takeda Pharmaceutical Company Limited, today announced a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE in patients with hemophilia A, presented as an oral presentation at the World Federation of Hemophilia Virtual Summit 2020.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
› Verified 8 days ago
| Entity Name | Curana Health Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255640678 PECOS PAC ID: 9133304603 Enrollment ID: O20110427000111 |
News Archive
Takeda Pharmaceutical Company Limited, today announced a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE in patients with hemophilia A, presented as an oral presentation at the World Federation of Hemophilia Virtual Summit 2020.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Raycho Genchev Kurkchijski, MD Po Box 844658, Dallas, TX 75284-4658 Ph: (254) 724-2111 | Mr Raycho Genchev Kurkchijski, MD 302 University Blvd, Round Rock, TX 78665-1032 Ph: (512) 509-0200 |
News Archive
Takeda Pharmaceutical Company Limited, today announced a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE in patients with hemophilia A, presented as an oral presentation at the World Federation of Hemophilia Virtual Summit 2020.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
› Verified 8 days ago
Larissa Kaye Oneill, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7200 Wyoming Spgs # 15000, Round Rock, TX 78681 Phone: 512-218-8696 Fax: 512-218-9532 | |
David Alan Diaz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15930 S Great Oaks Dr, A-200, Round Rock, TX 78681 Phone: 512-246-3338 Fax: 512-246-3368 | |
Dr. Aarti Prasad, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1001 S Mays St Ste 205, Round Rock, TX 78664 Phone: 254-577-9799 | |
Heather Celest Hammonds, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 302 University Blvd, Round Rock, TX 78665 Phone: 512-509-0200 | |
Sandeep Badyal, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1025 Sendero Springs Dr Ste 120, Round Rock, TX 78681 Phone: 737-220-7500 | |
Dr. Dana Ray Baker, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Chisholm Trail Rd Ste 450, Round Rock, TX 78681 Phone: 512-496-0394 Fax: 512-249-1719 | |
Dr. Anisha Virani, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 940 Hesters Crossing Rd, Round Rock, TX 78681 Phone: 512-244-9024 Fax: 512-406-7342 |